115 related articles for article (PubMed ID: 38071087)
1. Corrigendum to "Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma" [Bioorg. Chem. 129 (2022) 106124].
Barakat A; Alshahrani S; Al-Majid AM; Alamary AS; Haukka M; Abu-Serie MM; Dömling A; Mazyed EA; Badria FA; El-Senduny FF
Bioorg Chem; 2024 Feb; 143():107012. PubMed ID: 38071087
[No Abstract] [Full Text] [Related]
2. Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma.
Barakat A; Alshahrani S; Mohammed Al-Majid A; Saleh Alamary A; Haukka M; Abu-Serie MM; Dömling A; Mazyed EA; Badria FA; El-Senduny FF
Bioorg Chem; 2022 Dec; 129():106124. PubMed ID: 36174446
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators" [Bioorg. Chem. 117 (2021) 105427].
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2024 Feb; 143():107013. PubMed ID: 38087753
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2" [Bioorg. Med. Chem. 22 (2014) 4735-4744].
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2015 Aug; 23(15):5076. PubMed ID: 32689708
[No Abstract] [Full Text] [Related]
5. Corrigendum to "A novel monoterpenoid indole alkaloid with anticancer activity from Melodinus khasianus" [Bioorg. Med. Chem. Lett. 27 (2017) 893-896].
Zhou J; Feng JH; Robertson J; Fang L
Bioorg Med Chem Lett; 2020 Aug; 30(16):127294. PubMed ID: 32518059
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres" [Bioorg. Med. Chem. Lett. 24 (2014) 1062-1066].
Sheffler DJ; Nedelcovych MT; Williams R; Turner SC; Duerk BB; Robbins MR; Jadhav SB; Niswender CM; Jones CK; Conn PJ; Nathan Daniels R; Lindsley CW
Bioorg Med Chem Lett; 2017 May; 27(9):2079. PubMed ID: 28347668
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Design and synthesis of novel isatin-based derivatives targeting cell cycle checkpoint pathways as potential anticancer agents" [Bioorg. Chem. 105 (2020) 104366].
Yousef MA; Ali AM; El-Sayed WM; Qayed WS; Farag HHA; Aboul-Fadl T
Bioorg Chem; 2022 Mar; 120():105598. PubMed ID: 35032748
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction" [Bioorg. Med. Chem. Lett. 26 (2016) 2695-2700].
Jadhav GR; Sinha S; Chhabra M; Paira P
Bioorg Med Chem Lett; 2016 Aug; 26(16):4154-4155. PubMed ID: 27396504
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].
Fradera X; Methot JL; Achab A; Christopher M; Altman MD; Zhou H; McGowan MA; Kattar SD; Wilson K; Garcia Y; Augustin MA; Lesburg CA; Shah S; Goldenblatt P; Katz JD
Bioorg Med Chem Lett; 2020 Aug; 30(16):127363. PubMed ID: 32591133
[No Abstract] [Full Text] [Related]
10. Commentary to "The structure of McN-5652" [Bioorg. Med. Chem. 9 (2001) 2105] and to the corrigendum to "The structure of McN-5652" [Bioorg. Med. Chem. 10 (2002) 3368].
Maryanoff BE
Bioorg Med Chem; 2002 Oct; 10(10):3367. PubMed ID: 12150884
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activities" [Bioorg. Med. Chem. Lett. 20(23) (2010) 7110-7115].
Liang C; Ding Y; Nguyen HT; Kim JA; Boo HJ; Kang HK; Nguyen MC; Kim YH
Bioorg Med Chem Lett; 2021 Jun; 41():128014. PubMed ID: 33867227
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro" [Bioorg. Med. Chem. 27(2) (2019) 370-374].
Xu X; Peng W; Liu C; Li S; Lei J; Wang Z; Kong L; Han C
Bioorg Med Chem; 2022 Oct; 72():116998. PubMed ID: 36089430
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Design, synthesis, and biological evaluation of thiazole bioisosteres of goniofufurone through in vitro antiproliferative activity and in vivo toxicity" [Bioorg. Chem. 121 (2022) 105691].
Svirčev M; Popsavin M; Pavić A; Vasiljević B; Rodić MV; Djokić S; Kesić J; Srećo Zelenović B; Popsavin V; Kojić V
Bioorg Chem; 2022 Oct; 127():105984. PubMed ID: 35777235
[No Abstract] [Full Text] [Related]
14. Corrigendum to "A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives" [Bioorg. Med. Chem. Lett. 28 (14) (2018) 2481-2484].
Derabli C; Boualia I; Abdelwahab AB; Boulcina R; Bensouici C; Kirsch G; Debache A
Bioorg Med Chem Lett; 2018 Oct; 28(18):3129. PubMed ID: 30119958
[No Abstract] [Full Text] [Related]
15. Discovery of a cytochrome P450 enzyme catalyzing the formation of spirooxindole alkaloid scaffold.
Nguyen TM; Grzech D; Chung K; Xia Z; Nguyen TD; Dang TT
Front Plant Sci; 2023; 14():1125158. PubMed ID: 36818833
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to 'Betulinic acid induces apoptosis and inhibits metastasis of human colorectal cancer cells in vitro and in vivo' [Bioorg. Med. Chem. 27 (2019) 2546-2552].
Zeng A; Hua H; Liu L; Zhao J
Bioorg Med Chem; 2019 Oct; 27(19):115024. PubMed ID: 31416739
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Preventive effect of a novel diosgenin derivative on arterial and venous thrombosis in vivo" [Bioorg. Med. Chem. Lett. 26 (2016) 3364-3369].
Zheng H; Wei Z; Xin G; Ji C; Wen L; Xia Q; Niu H; Huang W
Bioorg Med Chem Lett; 2016 Sep; 26(17):4386. PubMed ID: 27474444
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents" [Bioorg. Med. Chem. 19 (2011) 5409-5419].
Kumar A; Tripathi VD; Kumar P; Gupta LP; Akanksha ; Trivedi R; Bid H; Nayak VL; Siddiqui JA; Chakravarti B; Saxena R; Dwivedi A; Siddiquee MI; Siddiqui U; Konwar R; Chattopadhyay N
Bioorg Med Chem; 2019 Sep; 27(17):3960-3961. PubMed ID: 31345744
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity" [Bioorg. Med. Chem. 25 (2017) 1524-1532].
Paraskevopoulos G; Monteiro S; Vosátka R; Krátký M; Navrátilová L; Trejtnar F; Stolaříková J; Vinšová J
Bioorg Med Chem; 2017 Apr; 25(8):2530. PubMed ID: 28285926
[No Abstract] [Full Text] [Related]
20. Corrigendum to "TCF3-activated FAM201A enhances cell proliferation and invasion via miR-186-5p/TNKS1BP1 axis in triple-negative breast cancer" [Bioorg. Chem. 104 (2020) 104301].
Jia H; Wu D; Zhang Z; Li S
Bioorg Chem; 2021 May; 110():104726. PubMed ID: 33676040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
